LAG3 and neoplasm: In melanoma mouse models, 9-ING-41 downregulates the expression of inhibitory immune checkpoints including PD-1 and LAG-3, resulting in synergistic anti-tumor activity when administered in combination with immune checkpoint inhibitors [79].